デフォルト表紙
市場調査レポート
商品コード
1085009

セクシャルヘルスの世界市場:製品タイプ別、性別、流通チャネル別、地域別-規模、シェア、展望、機会分析(2022年~2028年)

Sexual Health Market, by Product Type, by Gender, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 167 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
セクシャルヘルスの世界市場:製品タイプ別、性別、流通チャネル別、地域別-規模、シェア、展望、機会分析(2022年~2028年)
出版日: 2022年05月12日
発行: Coherent Market Insights
ページ情報: 英文 167 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

性的障害の発生率および有病率の増加は、市場の成長を増大させる主要な要因と考えられます。また、規制当局によるセクシャルヘルスに関する承認件数の増加も、市場の成長を促進することが期待されます。

当レポートでは、世界のセクシャルヘルス市場について調査しており、市場展望、市場力学、市場分析、競合情勢など、包括的な情報を提供しています。

目次

第1章 調査目的・前提条件

第2章 市場概要

  • レポートの説明
  • エグゼクティブサマリー
    • 市場の内訳:製品タイプ別
    • 市場の内訳:性別
    • 市場の内訳:流通チャネル別
    • 市場の内訳:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学、規制、および動向分析

  • 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析
  • 市場動向
  • 主な開発
  • 技術の進歩
  • 合併と買収
  • 業界動向
  • 規制シナリオ
  • ポーターの5つの力
  • PEST分析

第4章 世界のセクシャルヘルス市場:製品タイプ別(100万米ドル)(2017年~2028年)

  • イントロダクション
  • 勃起不全治療薬
  • 性別違和治療薬
  • 性的欲求低下障害治療薬
  • 早漏治療薬
  • その他

第5章 世界のセクシャルヘルス市場:性別(100万米ドル)(2017年~2028年)

  • イントロダクション
  • 男性
  • 女性

第6章 世界のセクシャルヘルス市場:流通チャネル別(100万米ドル)(2017年~2028年)

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 世界のセクシャルヘルス市場:地域別(100万米ドル)(2017年~2028年)

  • イントロダクション
  • 市場シェア分析(%)(2022年~2028年)
  • 前年比成長分析(2017年~2028年)
  • セグメント動向
  • 北米
  • 米国
  • カナダ
  • 欧州
  • 英国
  • ドイツ
  • イタリア
  • フランス
  • スペイン
  • ロシア
  • その他の欧州
  • アジア太平洋
  • 中国
  • インド
  • 日本
  • ASEAN諸国
  • オーストラリア
  • 韓国
  • その他のアジア太平洋
  • ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他のラテンアメリカ
  • 中東
  • GCC諸国
  • イスラエル
  • その他の中東
  • アフリカ
  • 北アフリカ
  • 中央アフリカ
  • 南アフリカ

第8章 競合情勢

  • ヒートマップ分析
  • 企業プロファイル
    • Teva Pharmaceutical Industries Ltd.
    • Meda Pharmaceuticals, Inc.
    • Eli Lilly & Company
    • Bayer AG
    • Vivus, Inc.
    • Zydus Pharmaceuticals
    • IVFTECH APS
    • Merck & Co.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd
    • Novartis International AG
    • Mylan Pharmaceuticals Inc.
    • AstraZeneca

第9章 セクション

目次
Product Code: CMI3364

Sexual health is an important part of a person's physical and mental health. Sexual health leads to the healthy sexual life without any sexual dysfunctions, and preventive measures to avoid sexually transmitted infections. The adult population largely suffers from one or more sexual disorders such as dyspareunia, erectile dysfunctions, hypoactive sexual desire disorder, premature (early) ejaculation, and others. According to National Center for Biotechnology Information 2016, sexual dysfunction is highly prevalent, and affects around 43% of women and 31% of men, globally. Currently, various treatment options such as medication, mechanical aids, sexual therapies, and others are available for treating such sexual dysfunctions and to improve sexual health of the person.

Market Dynamics

Increasing incidence and prevalence of sexual disorders is a major factor augmenting growth of the market. Some of the major factors which cause sexual dysfunction are aging population, stressful and unhealthy lifestyle, and other psychological parameters. According to a study published in the National Center for Biotechnology Information in April 2016, hypoactive sexual desire disorder (HSDD) is present in around 8.9% and 12.3% women in the age group of 18 - 44 years and 45 - 64 years, respectively.

Moreover, robust product development activities by major key players is engaged in the introduction of innovative and highly effective drug treatment for improving sexual health. For instance, in June 2019, AMAG Pharmaceuticals received the U.S. FDA approval for Vyleesi (bremelanotide) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Thus, increasing approvals by regulatory authorities are expected to drive the growth of the sexual health market.

Key features of the study:

  • This report provides in-depth analysis of the global sexual health market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles leading players in the global sexual health market based on the following parameters - company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, Inc., Eli Lilly & Company, Bayer AG, Vivus, Inc., Zydus Pharmaceuticals, IVFTECH APS, Merck & Co., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis International AG, Mylan Pharmaceuticals Inc., and AstraZeneca
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, government initiatives, technological upgradation, market expansion, and marketing tactics
  • The global sexual health market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the sexual health market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Sexual Health Market, By Product Type:
  • Erectile Dysfunction Drugs
  • Gender Dysphoria Drugs
  • Hypoactive Sexual Desire Disorder Drugs
  • Premature Ejaculation Drugs
  • Others
  • Global Sexual Health Market, By Gender:
  • Male
  • Female
  • Global Sexual Health Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Sexual Health Market, By Region:
  • North America
    • By Product Type:
  • Erectile Dysfunction Drugs
  • Gender Dysphoria Drugs
  • Hypoactive Sexual Desire Disorder Drugs
  • Premature Ejaculation Drugs
  • Others
    • By Gender:
  • Male
  • Female
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
    • By Country:
  • U.S.
  • Canada
  • Europe
    • By Product Type:
  • Erectile Dysfunction Drugs
  • Gender Dysphoria Drugs
  • Hypoactive Sexual Desire Disorder Drugs
  • Premature Ejaculation Drugs
  • Others
    • By Gender:
  • Male
  • Female
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Product Type:
  • Erectile Dysfunction Drugs
  • Gender Dysphoria Drugs
  • Hypoactive Sexual Desire Disorder Drugs
  • Premature Ejaculation Drugs
  • Others
    • By Gender:
  • Male
  • Female
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • By Product Type:
  • Erectile Dysfunction Drugs
  • Gender Dysphoria Drugs
  • Hypoactive Sexual Desire Disorder Drugs
  • Premature Ejaculation Drugs
  • Others
    • By Gender:
  • Male
  • Female
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • By Product Type:
  • Erectile Dysfunction Drugs
  • Gender Dysphoria Drugs
  • Hypoactive Sexual Desire Disorder Drugs
  • Premature Ejaculation Drugs
  • Others
    • By Gender:
  • Male
  • Female
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Product Type:
  • Erectile Dysfunction Drugs
  • Gender Dysphoria Drugs
  • Hypoactive Sexual Desire Disorder Drugs
  • Premature Ejaculation Drugs
  • Others
    • By Gender:
  • Male
  • Female
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Technology Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
    • Meda Pharmaceuticals, Inc.
    • Eli Lilly & Company
    • Bayer AG
    • Vivus, Inc.
    • Zydus Pharmaceuticals
    • IVFTECH APS
    • Merck & Co.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd
    • Novartis International AG
    • Mylan Pharmaceuticals Inc.
    • AstraZeneca

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description

1. Market Definition and Scope

  • Executive Summary

1. Market Snippet, By Product Type

2. Market Snippet, By Gender

3. Market Snippet, By Distribution Channel

4. Market Snippet, By Region

  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics

1. Drivers

2. Restraints

3. Market Opportunities

  • Impact Analysis
  • Market Trends
  • Key Developments
  • Technology Advancements
  • Merger and Acquisition
  • Regulatory Scenario
  • PORTER'S Five Forces
  • PEST Analysis

4. Global Sexual Health Market, By Product Type, 2017 - 2028, (US$ Million)

  • Introduction

1. Market Share Analysis, 2022 and 2028 (%)

2. Y-o-Y Growth Analysis, 2017 - 2028

3. Segment Trends

  • Erectile Dysfunction Drugs

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

  • Gender Dysphoria Drugs

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

  • Hypoactive Sexual Desire Disorder Drugs

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

  • Premature Ejaculation Drugs

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

  • Others

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Sexual Health Market, By Gender, 2017 - 2028, (US$ Million)

  • Introduction

1. Market Share Analysis, 2022 and 2028 (%)

2. Y-o-Y Growth Analysis, 2017 - 2028

3. Segment Trends

  • Male

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

  • Female

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Sexual Health Market, By Distribution Channel, 2017 - 2028, (US$ Million)

  • Introduction

1. Market Share Analysis, 2022 and 2028 (%)

2. Y-o-Y Growth Analysis, 2017 - 2028

3. Segment Trends

  • Hospital Pharmacy

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

  • Retail Pharmacy

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

  • Online Pharmacy

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Sexual Health Market, By Region, 2017 - 2028, (US$ Million)

  • Introduction

1. Market Share Analysis, By Region, 2022 and 2028 (%)

2. Y-o-Y Growth Analysis, By Region, 2017 - 2028

3. Regional Trends

  • North America

1. Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)

2. Market Size and Forecast, By Gender, 2017 - 2028, (US$ Million)

3. Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)

4. Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)

    • U.S.
    • Canada
  • Europe

1. Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)

2. Market Size and Forecast, By Gender, 2017 - 2028, (US$ Million)

3. Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)

4. Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)

    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific

1. Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)

2. Market Size and Forecast, By Gender, 2017 - 2028, (US$ Million)

3. Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)

4. Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)

    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America

1. Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)

2. Market Size and Forecast, By Gender, 2017 - 2028, (US$ Million)

3. Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)

4. Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)

    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East

1. Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)

2. Market Size and Forecast, By Gender, 2017 - 2028, (US$ Million)

3. Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)

4. Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)

    • GCC
    • Israel
    • Rest of Middle East
  • Africa

1. Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)

2. Market Size and Forecast, By Gender, 2017 - 2028, (US$ Million)

3. Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)

4. Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)

    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles

1. Teva Pharmaceutical Industries Ltd.

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

2. Meda Pharmaceuticals, Inc.

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

3. Eli Lilly & Company

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

4. Bayer AG

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

5. Vivus, Inc.

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

6. Zydus Pharmaceuticals

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

7. IVFTECH APS

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

8. Merck & Co.

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

9. Pfizer Inc.

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

10. Sun Pharmaceutical Industries Ltd

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

11. Novartis International AG

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

12. Mylan Pharmaceuticals Inc.

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

13. AstraZeneca

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact